###### What\'s new?

The EHRA score has been validated as a semi-quantitative measure of AF related symptoms and patients\' perception of their general state of health.A simple modification of the EHRA score (the mEHRA score) provides better discrimination for patients with mild to moderate symptoms.Patients with mild symptoms, which the patient does not find troublesome, have a Health-related Quality of Life comparable to asymptomatic patients suggesting they may not be appropriate candidates for intervention.

Introduction {#s1}
============

Atrial fibrillation (AF) is an emerging medical epidemic affecting 1--2% of the general population and up to 15% of elderly patients.^[@EUT395C1]--[@EUT395C4]^ As well as doubling mortality rate, there is a significant effect on morbidity due to symptoms such as palpitation, fatigue, dyspnoea, and exercise intolerance.^[@EUT395C5],[@EUT395C6]^ The resultant impact on quality of life (QoL) is as dramatic as for patients with severe structural heart disease.^[@EUT395C7]^ Up to one-third of patients present with limiting symptoms, and inpatient care is a major consumer of healthcare resources.^[@EUT395C8]^

In 2007, an expert group of the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) published recommendations for the conduct of clinical trials in AF.^[@EUT395C9]^ Noting that no accepted and easily applicable measure for the AF-related symptoms exists, this group of experts proposed and described in their recommendations a new scoring system, the EHRA classification, to assess and quantify symptoms related to AF.^[@EUT395C9]^ The EHRA classification is based on the impact of symptoms on daily activity during presumed episodes of AF. It is simple to use and has a format similar to the New York Heart Association (NYHA) symptom classification system for patients with heart failure, making it relatively intuitive for practicing clinicians while hopefully being more appropriate to AF-related symptoms.^[@EUT395C10]^ When the EHRA score was published, the authors made a specific mention of the need for validation.^[@EUT395C9]^ A similar score was thereafter validated by a Canadian group.^[@EUT395C6]^ Since its initial proposal, the EHRA score has entered widespread use and has even been used in the European Society of Cardiology guidelines for the management of AF in the recommendations for rate and rhythm control.^[@EUT395C11]--[@EUT395C16]^

To put the EHRA score into context with existing tools to assess disease-related QoL in AF patients, we compared the EHRA score with accepted and validated measures of health-related QoL. Specifically, we used both a disease specific tool, the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire, and a general tool, the very well-established EQ-5D questionnaire.^[@EUT395C17]--[@EUT395C19]^ The AFEQT is very sensitive to changes in symptom burden but cannot be compared with other conditions. EQ-5D, however, is applicable to a wide range of health conditions and provides a single index value for health status, called the health utility, which can be used to calculate 'quality-adjusted life years' (QALYs) for health economic evaluation.^[@EUT395C20]^ Previous studies have suggested that the minimal meaningful difference in the EQ-5D-derived health utility is 0.07.^[@EUT395C20]^ In line with this, a previous study of the cost-effectiveness of catheter ablation in the UK setting found catheter ablation to be cost-effective with an estimated utility difference of 0.09 between symptomatic AF on drugs compared with sinus rhythm following ablation.^[@EUT395C21]^

We aimed to validate the EHRA score by using these general and disease-specific QoL measures. We hypothesized that the discriminative power of the EHRA score could be improved and attempted to achieve this through a simple modification.

Methods {#s2}
=======

Phase 1 {#s2a}
-------

Consecutive patients with a diagnosis of AF attending designated heart rhythm/electrophysiology clinics at a single specialist cardiac hospital in England (Liverpool Heart and Chest Hospital) were invited to complete the AFEQT questionnaire and the EQ-5D instrument, including the visual analogue scale (VAS).^[@EUT395C18],[@EUT395C19]^ At the same clinical visit, the reviewing clinician was asked to independently score the patient according to the EHRA symptom classification. In keeping with real-world practice, these assessments were completed by a range of clinicians experienced in the management of patients with AF, including consultant cardiologists, trainee physicians, and arrhythmia nurses. Clinicians were provided with, and requested to complete, a classification form that listed the published definitions for each class. To replicate how the classification is likely to be used in routine practice, no specific training was provided beyond that described above and access to the original publication in which the EHRA score was proposed. This mirrored the methods used to validate an alternative classification system.^[@EUT395C6]^

Quality of life was assessed by the AFEQT score (global), the health-related utility based on the EQ-5D instrument, and the VAS. For each measure, a higher score represents a higher QoL. AFEQT and VAS are scored from 0 to 100. Health utility (EQ-5D) ranges between 1 (perfect health) through 0 (death) to −0.59 (worse than death). Mean QoL scores were compared between neighbouring EHRA classes to assess the classification system\'s accuracy in semi-quantifying QoL.

Phase 2 {#s2b}
-------

We proposed a modified EHRA (mEHRA) classification by subdividing Class 2 into Classes 2a (mild) and 2b (moderate) according to the degree to which the patient was 'troubled by their symptoms' (*Table [1](#EUT395TB1){ref-type="table"}*). All the patients categorized as Class 2 during Phase 1 of the study were independently re-categorized as either Class 2a or 2b by two clinicians (electrophysiology fellows) who were both blinded to the corresponding QoL scores. Clinical letters were reviewed with specific attention made to the extent to which the patients appeared 'troubled by their symptoms', given that their daily activities were not affected (which would indicate Class 3 symptoms). We sought to assess the patient\'s own perception of the impact of AF on their well-being. Those suffering from anxiety, loss of confidence, or symptoms that they found unpleasant were graded as Class 2b. There was agreement between the reviewers for all the cases reclassified into mEHRA Classes 2a and 2b. Where the clinical letters were lacking in detail, the hospital records were re-reviewed and a consensus agreed upon. The mEHRA score was assessed and validated using the same methods used to validate the EHRA score in the initial phase of the study. Table 1Modified EHRA (mEHRA) classificationmEHRA scoreSymptomsDescription1None2aMildNormal daily activity not affected, [symptoms not troublesome to patient]{.ul}2bModerateNormal daily activity not affected [but patient troubled by symptoms]{.ul}3SevereNormal daily activity affected4DisablingNormal daily activity discontinued[^1]

Phase 3 {#s2c}
-------

Having completed Phases 1 and 2, we wished to verify and validate the findings from our retrospective scoring of the mEHRA score, by comparing our findings with an independent cohort in whom the mEHRA score had been used prospectively. The method of data collection for this phase matched exactly with that in Phase 1, except that the clinicians were asked to classify symptoms according to the new, expanded mEHRA score rather than the original EHRA score. We compared the prospective and the retrospective scores, for the two new mEHRA classes, for each of the three QoL measures used in the previous two phases.

Atrial Fibrillation Effect on QualiTy-of-Life questionnaire {#s2d}
-----------------------------------------------------------

The AFEQT questionnaire is a validated, disease-specific, self-administered QoL instrument.^[@EUT395C17]^ It has 20 questions with four conceptual domains: symptoms (four questions specifically targeted to assess AF-related symptoms), Treatment Concerns (six questions that assess AF treatment concerns in patients), Daily Activities (eight questions that evaluate daily function in AF patients), and Treatment Satisfaction (two questions asking about how well the current treatment controls their AF and relieves symptoms). Each of the 20 questions is marked on a 7-point Likert scale. A published algorithm exists to allow the calculation of a score, between 0 and 100 (where higher is better), for each domain and a global score based on the first three domains. The questionnaire specifies a recall period of the preceding 4 weeks.

EQ-5D questionnaire (Three-level version) {#s2e}
-----------------------------------------

EQ-5D is a standardized measure of health status developed by the EuroQol Group to provide a simple, generic measure of health for clinical and economic appraisal.^[@EUT395C18]^ Two hundred and forty-three possible health states can be defined from the five questions and these can be converted into a single summary index called the 'health utility' based on country-specific value sets.^[@EUT395C22]^ The health utility measure is of particular interest as it is generalizable to other diseases and to the general population. Therefore, it allows the calculation of QALYs and thus the cost-effectiveness of interventions such as catheter ablation.

Visual analogue scale {#s2f}
---------------------

The VAS forms an integral but distinct part of the EQ-5D instrument. Respondents are asked to mark a single point on a linear scale that represents their health status on the day of completion. The scale extends from 0 (worst imaginable health state) to 100 (best imaginable health state). The VAS provides a quantitative measure of state of health, as judged by the individual patients.

Statistical analysis {#s2g}
--------------------

Analyses were performed using StatsDirect software version 2.7.8. Analysis of QoL scores (AFEQT score, EQ-5D-derived utility, and VAS) using the Shapiro--Wilk *W* test showed non-Gaussian distribution that was not corrected by logarithmic transformation. However, the central limit theorem is generally taken to imply that an assumption of normality is not necessary for parametric testing to be valid if the group sizes are greater than about 30. This is the case for all but one group in our analysis. In addition, presentation of the data as means with standard deviation was adjudged to be of greater clinical relevance than presentation of medians with the inter-quartile ranges. Continuous data are therefore presented as mean ± standard deviation and compared using the *t*-test. A similar approach has been used in previous work using QoL measures.^[@EUT395C23]^ A two-tailed test was used where there was no *a priori* expectation of the direction of the difference between the groups. However, where a comparison was made between two adjacent groups, resulting in assessment for a difference in a single direction only, one-tailed testing was considered more appropriate. Analysis of variance was compared by using one-way analysis of variance (ANOVA). Trend across groups was assessed by using Cuzick\'s test. Proportions were compared by using the *χ*^2^ statistic. Intra- and inter-observer variability were calculated, and assessed by using the *κ* statistic. A *P* value of 0.05 or lower was considered significant for all tests.

The study was performed as part of a wider institutionally approved patient reported outcome measures service improvement programme at the recruiting centre.

Results {#s3}
=======

Quality of life and symptom data were collected on 362 patients attending the heart rhythm clinics during 2012. All patients received physician-allocated EHRA classification at the same clinical visit. The baseline characteristics are given in *Table [2](#EUT395TB2){ref-type="table"}*. There were no clear differences between the groups in terms of age, sex, or proportion classified as having paroxysmal, as opposed to persistent or permanent, AF. Previous studies have found QoL to be lower in females.^[@EUT395C24]^ However, in our cohort, patient gender did not have a significant effect on any of the three QoL measures (EQ-5D *P* = 0.56, VAS *P* = 0.70, and AFEQT *P* = 0.14). Hypertension was by far the most common comorbid condition (48.6% of all patients) and showed a significant trend towards increasing prevalence in higher EHRA classes (*P* = 0.003). Other comorbidities were infrequently present and were similar across classes. However, there was a clear trend seen whereby those in less severe symptom classes were the most likely to have previously undergone ablation and those in the most severe classes were considerably more likely to subsequently go on to have an ablation for atrial fibrillation. (*P* \< 0.0001 for both). A small proportion of asymptomatic patients went on to have an ablation in keeping with the published data from the EUR Observation study where 13% of patients were asymptomatic, citing a desire for a drug free lifestyle, improved QoL, and/or the maintenance of sinus rhythm.^[@EUT395C25]^ Table 2Baseline characteristics by EHRA classEHRA 1EHRA 2EHRA 3EHRA 4Total*P* value for trend*N*, number149999024362n/aAge (mean ± SD)61.1 (±11.4)59.7 (±12.2)57.9 (±13.0)62.2 (±9.9)60.0 (±12.0)NCMale gender70.3%58.6%73.0%62.5%66.9%NC% PAF^a^49.0%65.6%62.2%41.7%56.4%0.36Diabetes6.8%7.1%8.8%20.0%8.3%NCHeart failure5.4%3.0%7.7%12.0%5.8%NCHypertension54.4%36.4%46.2%72.0%48.6%0.003Pacemaker5.4%7.1%9.9%12.0%7.5%NCCOPD4.8%6.1%8.8%4.0%6.1%NCPrevious stroke/TIA8.2%6.1%13.2%12.0%9.1%NCPrior ablation77.6%52.5%25.3%24.0%53.9%\<0.0001Subsequent ablation6.8%34.3%61.5%76.0%32.9%\<0.0001[^2][^3][^4]

Phase 1 {#s3a}
-------

Results for the three QoL measures are shown in *Table [3](#EUT395TB3){ref-type="table"}* and *Figure [1](#EUT395F1){ref-type="fig"}*. Analysis of variance and regression analysis confirmed significant negative correlation between the EHRA class and QoL as assessed by all three measures. To determine the ability of the EHRA classification as a semi-quantitative tool, each EHRA class was compared with the class immediately below in terms of QoL (i.e. EHRA 2 with EHRA 1, EHRA 3 with EHRA 2, and EHRA 4 with EHRA 3). On using the disease-specific AFEQT score, significant differences were seen at each grade boundary suggesting that the EHRA score was an effective means of categorizing patients\' symptoms. Similarly, on using the patient-based VAS, there was a significant difference between each and its immediate neighbour suggesting that the EHRA score effectively categorized patients in terms of their own assessment of their health state. However, when comparing the health-related utility, derived from the EQ-5D questionnaire, although there was a significant difference of 0.12 (*P* \< 0.001) between Classes 2 and 3, the difference between Classes 1 and 2 was only 0.04 (*P* = 0.08). This observation prompted us to develop the mEHRA classification. Table 3Mean (and standard deviation) shown for each EHRA classEHRA classUtility (by EQ-5D)*P* valueVAS*P* valueAFEQT*P* value10.85 (±0.21)n/a76.2 (±19.9)n/a78.4 (±19.0)n/a20.81 (±0.17)0.0870.3 (±20.3)0.0263.6 (±20.0)\<0.000130.69 (±0.27)\<0.00159.6 (±21.9)\<0.00142.1 (±21.1)\<0.000140.59 (±0.29)0.0846.9 (±25.9)0.0331.3 (±18.6)0.01[^5][^6] Figure 1Quality of life (QoL) scores (mean ± standard deviation) by EHRA class.

Phase 2 {#s3b}
-------

Of the 99 patients originally classified as EHRA Class 2, 90 had sufficient detail in their archived clinical letters to be reclassified in accordance with the proposed mEHRA classification into either Class 2a or 2b. Of these, 43 were classified as Class 2a and 47 were classified as Class 2b. The subdivision of Class 2 into Classes 2a and 2b, resulted in clearly separate groups, with the Class 2a patients having AFEQT scores and health utilities much closer to the Class 1 patients and the Class 2b patients having significantly more symptoms as judged by the AFEQT and a significant reduction in the health utility as judged by the EQ-5D. The results are shown in *Table [4](#EUT395TB4){ref-type="table"}* and *Figure [2](#EUT395F2){ref-type="fig"}*. Table 4Mean (and standard deviation) shown for each mEHRA classmEHRA classUtility (by EQ-5D)*P* valueVAS*P* valueAFEQT*P* value10.85 (±0.21)n/a76.2 (±19.9)n/a78.4 (±19.0)n/a2a0.86 (±0.18)0.4175.6 (±19.9)0.4370.9 (±19.8)0.012b0.77 (±0.15)0.0165.2 (±20.1)0.0158.3 (±17.3)\<0.00130.69 (±0.27)0.0259.6 (±21.9)0.0942.1 (±21.1)\<0.000140.59 (±0.29)0.0846.9 (±25.9)0.0331.3 (±18.6)0.01[^7][^8] Figure 2Quality of life (QoL) scores (mean ± standard deviation) by mEHRA class. Classes 1, 3, and 4 are as for *Figure [1](#EUT395F1){ref-type="fig"}*. Class 2 has been split into Classes 2a (*n* = 43) and 2b (*n* = 47).

We also analysed the mEHRA class according to the three subdomains of the AFEQT score: Symptoms, Activities, and Concerns. As can be seen in *Figure [3](#EUT395F3){ref-type="fig"}*, there is a clear step-wise trend to lower scores as the mEHRA class increases. As these components of the AFEQT global score are not themselves individually validated we did not seek to analyse these on a class-by-class basis. However, the ANOVA confirmed a highly significant difference between the groups for all three subdomains (*P* \< 0.0001 for each) and Cuzick\'s trend test showed a strong, and highly significant, trend towards lower scores with increasing mEHRA class (*P* \< 0.0001 for each of the three subdomains). Figure 3AFEQT sub-domain scores (mean ± standard deviation) by mEHRA class.

Reproducibility of the modified European Heart Rhythm Association class {#s3c}
-----------------------------------------------------------------------

To assess the reproducibility of the mEHRA score we measured both intra-observer and inter-observer variability. Agreement between the two assessors for the ratings of Class 2a or 2b was very good at 83.2% (*κ* 0.70, 95% confidence interval (CI) = 0.53--0.87). Inter-observer variability was assessed by asking each assessor to re-classify a random sample of 20 of the original clinical letters used for Phase 2 of the study. This was performed after an interval of several months to avoid bias due to recall of the previous classification. This demonstrated excellent repeatability, with an agreement between the original and the repeat classification of 90% for one assessor and 95% for the other (combined *κ* 0.85, 95% CI for *κ*, 0.54--1.16).

Phase 3: prospective validation of the modified European Heart Rhythm Association {#s3d}
---------------------------------------------------------------------------------

The mEHRA score was thereafter prospectively applied to a second cohort of patients attending the Heart Rhythm Clinics at Liverpool Heart and Chest Hospital. By using the modified scoring system, 165 patients were classified as either Class 2a (*n* = 85) or 2b (*n* = 80). These data are shown in *Table [5](#EUT395TB5){ref-type="table"}*. Prospective scoring showed the same pattern as retrospective scoring with significantly lower AFEQT, EQ-5D, and VAS scores for mEHRA Class 2b than Class 2a. There were no significant differences between any of the three QoL measures between this validation cohort and the initial cohort in either of the two new mEHRA classes (2a and 2b). Table 5Comparison of retrospective and prospective QoL scores, for each of the two proposed additional mEHRA classesQoL measureRetrospective\
*n* = 90Prospective\
*n* = 165*P* value\
Retrospective vs. prospectiveUtility (EQ-5D)2a0.86 (±0.18)0.81 (±0.22)0.232b0.77 (±0.15)0.72 (±0.22)0.25*P* value 2a vs. 2b*P* = 0.01*P* \< 0.0001VAS2a75.6 (±19.9)77.9 (±15.9)0.512b65.2 (±20.1)67.0 (±16.4)0.60*P* value 2a vs. 2b*P* = 0.01*P* = 0.009AFEQT2a70.9 (±19.8)67.7 (±22.2)0.422b58.3 (±17.3)54.1 (±20.2)0.25*P* value 2a vs. 2b*P* \< 0.001*P* \< 0.0001

Discussion {#s4}
==========

This comparison of the EHRA symptoms classification with one disease-specific QoL instrument (AFEQT) and another general measure for the health-related QoL (EQ-5D, incorporating the VAS) provides good evidence that the EHRA score can be used to assess AF-related symptoms without prior training. It is easily applied in clinical practice and has the potential to be useful in clinical trials. However, it does not discriminate sufficiently in patients with low-level symptoms in terms of the health-related utility. We found that the EHRA classification can be improved by subdividing Class 2 into two separate classes (2a and 2b).

Phase 1 of this study provides evidence that the EHRA classification, in its originally proposed format correlates well with the disease-related QoL, as judged by the AFEQT questionnaire and with the patients\' own perception of their health state (VAS). There is a step-wise, negative association between the EHRA class and both of these measures. The EHRA score can therefore be considered as a validated tool for symptom classification. In a similar manner to the NYHA functional class for heart failure and the Canadian Cardiovascular Society angina scale, the EHRA score allows clinicians to broadly categorize the severity of patients\' symptoms. Where the specifics and the complexities of symptoms can be considerable, this sort of categorization provides a simple means of communicating and quantifying symptom severity. It allows a cross-sectional comparison between patients and a longitudinal comparison for individual patients or groups of patients.

However, using health-related utility as a measure of QoL, the EHRA score only showed significant discriminatory power at the boundary between mild (Class 2) and severe (Class 3) symptoms. To try to improve the discriminative ability for patients with mild--moderate symptoms, we subdivided the EHRA Class 2 patients into Classes 2a and 2b, based on the degree to which the patients were 'troubled by their symptoms', and found that the two subdivisions were significantly different from each other on all three QoL measures. Indeed, the health-related utility showed no significant difference between Class 1 (asymptomatic patients) and Class 2a (patients with symptoms but which are not troublesome and do not affect daily activity). Class 2b patients showed a significant reduction (0.09) in health utility compared with Class 2a patients (*Table [4](#EUT395TB4){ref-type="table"}*). As such it may be more appropriate to base the treatment decisions not simply on the presence or the absence of symptoms, but also on whether the symptoms cause trouble to the patient or not.

At first sight, the EQ-5D questionnaire does not intuitively represent a sensitive QoL assessment for a patient with AF. The value in its use, however, is the assessment of a health utility score at baseline, which can then be reassessed following treatment. This allows calculation of the cost-efficacy of the intervention, and thereby a comparison of medical interventions between different disciplines. There is a growing demand in all countries to understand the cost-effectiveness of treatments used for common conditions to ensure the efficient and appropriate use of health resources. This is particularly the case when considering potentially costly treatments such as catheter ablation. In addition, there is an increasing focus on the patient reported health status as the most relevant outcome of medical interventions, and as clinicians we should embrace this method of assessing outcomes.^[@EUT395C26]^

The EQ-5D QoL questionnaire has previously been studied in AF, although not in association with the EHRA score. Berg *et al*.^[@EUT395C27]^ reported the findings from the EQ-5D in the Euro Heart Survey. The EQ-5D was completed by 5050 patients attending specialist hospital departments in 35 European countries. The population studied was somewhat older than ours with a mean age of 66 years. The mean utility was 0.75, which would suggest that most patients had a symptom level around mEHRA Class 2b. A repeat survey after 1 year completed by 3045 patients showed only a minor (0.013) improvement in the health utility. A lower health utility was associated with AF-specific symptoms, but also other variables including increasing age, history of stroke, and the inability to take regular exercise. Only 2.5% of the patients enroled into the Euro Heart Survey received treatment with catheter ablation.^[@EUT395C28]^ A sub-analysis of the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study, looking at an older population (mean age 82, range 75--99) showed a comparable baseline utility for males (0.77) but a lower utility for females (0.68).^[@EUT395C24]^

In assessing interventions, doctors often focus on observable events, such as the frequency and the duration of AF episodes, which may not tally with the patients\' perspective of their QoL.^[@EUT395C7],[@EUT395C29]^ The motivation of a patient to seek treatment, however, is based on the hope that symptoms will improve. We propose that the reclassification of EHRA Class 2 into Classes 2a and 2b can be of clinical use in selected patients with moderate AF-related symptoms. The reclassification of EHRA Class 2 is focused on the impact that AF has on the patient, by stating either that AF symptoms are 'not troublesome to patient' (Class 2a) or that the 'patient is troubled by symptoms' (Class 2b). This distinction will be intuitive for many clinicians, and appears as easily applicable as the original score. From our results, we can see that this clearly differentiates the two groups with not only a statistically significant difference in the health utility, but with an absolute difference of 0.09, a clinically meaningful difference.

Limitations {#s4a}
-----------

The EHRA score, and by extension the mEHRA score, is intended to be used for patients with either paroxysmal or non-paroxysmal AF and we did not differentiate between the two types in our analyses. It is conceivable that, within an individual mEHRA class, there is a difference in the QoL between the two AF types. The subdivision of EHRA Class 2 in Phase 2 was performed retrospectively by using clinical letters and could be considered subjective as it was based on a judgement of whether the patient was 'troubled by their symptoms'. This was however performed by two independent physicians, who were both blinded to the QoL scores of the patients in Phase 1 of the study. In a small minority of cases (*n* = 9), subdivision was not possible because of inadequate details in the clinical letter and therefore these patients could not be included in Phase 2. By looking at and comparing a prospective cohort, we have shown that retrospective scoring is unlikely to have a significant effect on the conclusions drawn. In addition, although our assessments were made by a range of healthcare providers, all were experienced in the management of patients with AF and the population studied is from a specialist tertiary centre where a large proportion of patients are managed invasively. The classification may be less appropriately used in the hands of others groups of physicians or nurses or in other patient populations. Within these limitations, the mEHRA appears a practicable and useful addition to the EHRA score.

Conclusions {#s5}
===========

The EHRA classification, as originally proposed, is a valid means of quantifying AF symptom severity and correlates well with AFEQT and with the generic EQ-5D. Subdividing EHRA Class 2 into Classes 2a and 2b by a single additional question has the potential to discriminate two clearly separate groups, with Class 2b patients having significantly impaired QoL due to AF, whereas those with Class 2a symptoms do not differ significantly from asymptomatic patients. This simple modification may further improve the clinical usefulness of the EHRA score, particularly when considering interventions such as ablation, where Class 2b symptoms appear to be the appropriate treatment threshold.
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[^1]: Underlined text represents the modification to the original descriptions of EHRA classes.

[^2]: NC, not calculated (where ANOVA revealed no significant variance between groups, a test for trend was not performed).

[^3]: ^a^Predominant pattern at time of assessment.

[^4]: COPD, chronic obstructive pulmonary disease; TIA, transient ischaemic attack; PAF, paroxysmal atrial fibrillation. The term 'ablation' is used to denote catheter ablation of atrial fibrillation (e.g. pulmonary vein isolation).

[^5]: *P* values compare each class with the next lowest class in terms of symptom severity.

[^6]: VAS, visual analogue scale; AFEQT, AFEQT global score.

[^7]: *P* values compare each class with the next lowest class in terms of symptom severity.

[^8]: VAS, visual analogue scale; AFEQT, AFEQT global score.
